NCT00016068View on ClinicalTrials.gov

Valganciclovir to Prevent Cytomegalovirus Infection in Patients Following Donor Stem Cell Transplantation

PHASE3CompletedINTERVENTIONAL
Enrollment

184

Participants

Timeline

Start Date

January 31, 2001

Study Completion Date

September 30, 2007

Conditions
Infection
Interventions
DRUG

ganciclovir

DRUG

valganciclovir

Trial Locations (7)

10021

Memorial Sloan-Kettering Cancer Center, New York

55905

Mayo Clinic Cancer Center, Rochester

91010-3000

City of Hope Comprehensive Cancer Center, Duarte

32610-0232

University of Florida Shands Cancer Center, Gainesville

48201-1379

Barbara Ann Karmanos Cancer Institute, Detroit

77030-4009

M.D. Anderson Cancer Center at University of Texas, Houston

98109-1024

Fred Hutchinson Cancer Research Center, Seattle

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Fred Hutchinson Cancer Center

OTHER

NCT00016068 - Valganciclovir to Prevent Cytomegalovirus Infection in Patients Following Donor Stem Cell Transplantation | Biotech Hunter | Biotech Hunter